Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)

Inclusion Criteria

• Chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) that warrants treatment
• Adequate organ system function as specified in the protocol
• Ability to follow protocol procedures.

Exclusion Criteria

• Subjects receiving cancer therapy or any investigational drug within 21 days of Cycle 1, Day 1
• Prior exposure to any PI3K inhibitor or venetoclax
• Autologous hematologic stem cell transplant within 6 months of study entry. Prior allogeneic hematologic stem cell transplant is excluded
• Active Hepatitis B or Hepatitis C.